Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India

SINGAPORE, Nov. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
November 07, 2025 16:30 ET | Source: Cellectis Inc.

Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update

Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel...
November 06, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy

SINGAPORE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
November 04, 2025 08:00 ET | Source: Azalea Therapeutics

Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each Patient

Azalea Therapeutics launches with $82M to advance precision in vivo genome engineering, creating therapeutic cells directly inside patients.
November 03, 2025 11:57 ET | Source: Spherix Global Insights

Gene and Cell Therapies Emerge as Front-Runners in Neurology Innovation, with High Expectations in ALS, Parkinson’s, and Neuroimmune Disorders

EXTON, PA, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Spherix Global Insights’ latest Special Topix™: Neurology Pipeline Opportunities 2025 (US) service captures forward-looking insights from 79 U.S....
November 03, 2025 09:15 ET | Source: Cellectis Inc.

Cellectis to Present a Development Update for eti-cel at ASH 2025

Preliminary data recently shared for eti-cel (UCART20x22) show an 86% ORR and a 57% CR rate (n=7), underscoring its potential to improve outcomes in r/r NHLPreclinical data demonstrated that combining...
October 23, 2025 09:30 ET | Source: SNS Insider pvt ltd

Cancer Gene Therapy Market to Reach USD 17.35 Billion by 2032, Spread of Personalized Treatments Increasing – SNS Insider

Austin, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cancer Gene Therapy Market Size & Growth Analysis: According to SNS Insider, the global Cancer Gene Therapy Market size was valued at USD 4.07 billion...
October 22, 2025 08:00 ET | Source: CYTOMED THERAPEUTICS LIMITED

CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%

SINGAPORE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire

○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2...
October 16, 2025 15:19 ET | Source: Cellectis Inc.

Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL

○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated...